Results 201 to 210 of about 88,273 (287)

Investigation of the “Not Better Explained” Diagnosis Criteria in Sleep Disorder Classifications: A Systematic Content Analysis and Critical Review

Journal of Sleep Research, EarlyView.
The “Not Better Explained” (NBE) criterion plays a key role in preventing diagnostic misclassification by structuring causal reasoning in sleep medicine. This systematic content analysis compares the use, wording, and excluded conditions of NBE criteria across the ICSD‐3‐TR and DSM‐5‐TR for ten major sleep disorders.
Jean‐Arthur Micoulaud‐Franchi, Vincent P. Martin, Julien Coelho, Régis Lopez, Pierre‐Alexis Geoffroy, Laure Peter‐Derex, Isabelle Lambert, Charles M. Morin, Clélia Quiles, Christophe Gauld   +9 more
wiley   +1 more source

Clinical and non-clinical aspects of reimbursement policy for orphan drugs in selected European countries. [PDF]

Front Pharmacol
Jakubowski S, Holko P, Nowak R, Warmuth M, Dooms M, Salminen O, Cortial L, Selke GW, Georgi C, Magnússon E, Crisafulli S, Strijbosch F, Mueller T, Grieve E, Danés I, Kawalec P.   +15 more
europepmc   +1 more source

Estimating the minimal cost of delivering nutrition‐specific and nutrition‐sensitive interventions in Ethiopia

Maternal &Child Nutrition, EarlyView.
The minimum cost of the 10 years on identified nutrition‐specific and nutrition‐sensitive interventions of the National Food and Nutrition Strategy in Ethiopia is estimated to be US$ 2.55bn with an average annual cost of $250 million over 10 years (2021–2030), which is only 2.3% of the Ethiopian Annual GDP 111.27 billion US dollars in 2021 (World bank).
Yetayesh Maru, Firehiwot Mesfin, Arnaud Laillou, Ramadhani Noor, Shiva Raj Adhikari, Meseret Zelalem, Hiwot Darsene, Solomon Memire, Andarge Abie, Stanley Chitekwe   +9 more
wiley   +1 more source

Orphan drugs: The final frontier in the fight against rare diseases.

Indian J Pharmacol
Rajaram S, Medhi B.
europepmc   +1 more source

Results of health technology assessments of orphan drugs in Germany-lack of added benefit, evidence gaps, and persisting unmet medical needs. [PDF]

Int J Technol Assess Health Care
Kranz P, McGauran N, Ünal C, Kaiser T.
europepmc   +1 more source

Higher Objectives of Islamic Law (Maqāṣid al‐Sharīʿa) in Substantiating Justice in Land Tax

The Muslim World, EarlyView.
Abstract This article discusses the relationship between the systemization of kharāj (land tax) and the higher objective of Islamic law or Maqāṣid al‐Sharīʿa. After the conquest of Sawād region (located in modern‐day southern Iraq), the First Caliph ʿUmar (634 ‐ 644 CE) introduced a new approach to the distribution of ghanīmah (spoils of war), leaving ...
Öznur Özdemir, Mehmet Asutay
wiley   +1 more source

Implementation status of pharmacological studies in the development of orphan drugs. [PDF]

Orphanet J Rare Dis
Yokoshiki S, Arato T.
europepmc   +1 more source

Estimating Correlations Between Clinical Trial Outcomes Using Generalised Estimating Equations

Oxford Bulletin of Economics and Statistics, EarlyView.
ABSTRACT Accurately estimating the correlations among clinical trial outcomes is crucial for managing the risk of biopharmaceutical investment portfolios. We propose a novel algorithm for estimating correlations in large clinical trial datasets using a generalised estimating equations (GEE) framework.
Yuehao Dai, Andrew W. Lo, Manish Singh, Qingyang Xu, Ruixun Zhang   +4 more
wiley   +1 more source

Prolonged exposure to artificial light and carcinogenesis: A systematic review of oncostatic mechanisms associated with melatonin pathways

Photochemistry and Photobiology, EarlyView.
Exposure to artificial light at night (ALAN), particularly at blue wavelengths, disrupts circadian rhythms by suppressing melatonin, thereby increasing cancer susceptibility. This systematic review consolidates evidence linking prolonged ALAN exposure to an elevated risk of breast and prostate tumors.
Gabriel Barboza, Jêmina Oliveira, Antônio Ferreira, Renan Lopes, Marli Cupertino   +4 more
wiley   +1 more source

Development of the Emirates Multi-Criteria Decision Analysis Tool for Orphan Drugs. [PDF]

Cureus
Alnaqbi KA, Elezbawy B, Fasseeh AN, Bangash AR, Elshamy A, Shendi H, Aftab MI, AlMarshoodi M, Gebran N, AlDhaheri N, Fahmy SA, Al Dallal S, Al Naeem W, Abaza S, Kaló Z.   +14 more
europepmc   +1 more source